By Linda Wang – UCLA Newsroom –
Ovarian cancer is the leading cause of death among women with gynecological cancers. The current medical playbook — surgery followed by chemotherapy — initially shows promise. Tumors shrink, sometimes disappearing entirely. But in more than 80% of patients, the cancer not only comes back, but returns more aggressive and increasingly resistant to the very treatments that once seemed effective.
But now, there could be new hope. In a study published in the journal Med, UCLA researchers have detailed their development of a new type of immune cell therapy, called CAR-NKT cell therapy, that could transform ovarian cancer care by delivering superior cancer-fighting power.
